[1]JournalofMedicinalChemistry,2013,vol.56,#2,p.427-436
[1]JournalofMedicinalChemistry,2013,vol.56,#2,p.427-436
[1]JournalofMedicinalChemistry,2013,vol.56,#2,p.427-436
[1]JournalofMedicinalChemistry,2013,vol.56,#2,p.427-436
[1]JournalofMedicinalChemistry,2013,vol.56,#2,p.427-436
[1]JournalofMedicinalChemistry,2013,vol.56,p.427-436
[1]JournalofMedicinalChemistry,2013,vol.56,p.427-436
[1]JournalofMedicinalChemistry,2013,vol.56,p.427-436
[1]JournalofMedicinalChemistry,2013,vol.56,p.427-436
[1]JournalofMedicinalChemistry,2013,vol.56,p.427-436
Title: Marek L, et al. Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells. J Med Chem. 2013 Jan 24;56(2):427-36.
Title: Li A, et al. HDAC5, a potential therapeutic target and prognostic biomarker, promotes proliferation, invasion and migration in human breast cancer. Oncotarget. 2016 Jun 21;7(25):37966-37978.
Title: Trazzi S, et al. HDAC4: a key factor underlying brain developmental alterations in CDKL5 disorder. Hum Mol Genet. 2016 Sep 15;25(18):3887-3907.